<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01908933</url>
  </required_header>
  <id_info>
    <org_study_id>03-C13-001PLV</org_study_id>
    <nct_id>NCT01908933</nct_id>
  </id_info>
  <brief_title>Study of the AeriSeal System Treatment in Patients With Advanced Non-Upper Lobe Predominant Heterogeneous Emphysema</brief_title>
  <official_title>Study of the AeriSeal System Treatment in Patients With Advanced Non-Upper Lobe Predominant Heterogeneous Emphysema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aeris Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aeris Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to prospectively evaluate the safety and efficacy of the&#xD;
      AeriSeal System in patients with advanced Non-Upper Lobe Predominant Heterogeneous Emphysema.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective single arm study to evaluate the safety and efficacy of the AeriSeal&#xD;
      System in patients with advanced Non-Upper Lobe Predominant Heterogeneous Emphysema.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Anticipated">November 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Volume change by CT</measure>
    <time_frame>28 - 30 weeks</time_frame>
    <description>Group mean normalized change from baseline in the volume of the treated lung lobes measured by quantitative CT at 24 weeks post-treatment (defined as the sum of volume change in all treated lobes/number of treatments).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fraction of patients showing clinically significant improvements from baseline in one or more of the following outcomes at 24 weeks post treatment: Forced Expiratory Volume in 1 second (FEV1), Forced Vital Capacity (FVC), Medical Research Council Dyspnea</measure>
    <time_frame>28 - 30 weeks</time_frame>
    <description>Group mean change in baseline to week 24 in:Forced Expiratory Volume in 1 second (FEV1),Forced Vital Capacity (FVC),Medical Research Council Dyspnea (MRCD), 6 Six-Minute Walk Test (6MWT), Saint George Respiratory Questionnaire (SGRQ)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Emphysema</condition>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>AeriSeal Emphysematous Lung Sealant Syst</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a prospective, open label, single-arm, multicenter, investigational study. Patients will receive either unilateral or bilateral AeriSeal System therapy as appropriate utilizing 20 mL/subsegment dosing at 2 to 4 subsegments.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AeriSeal Emphysematous Lung Sealant Syst</intervention_name>
    <description>This is a prospective, open label, single-arm, multicenter, investigational study. Patients will receive either unilateral or bilateral AeriSeal System therapy as appropriate utilizing 20 mL/subsegment dosing at 2 to 4 subsegments.</description>
    <arm_group_label>AeriSeal Emphysematous Lung Sealant Syst</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing and able to provide informed consent and to participate in the study&#xD;
&#xD;
          -  Age &gt; or = 40 years at the time of the screening&#xD;
&#xD;
          -  Advanced lower or lower and upper lobe predominant heterogeneous emphysema by CT scan&#xD;
&#xD;
          -  Minimum of 2 subsegments appropriate for treatment&#xD;
&#xD;
          -  MRCD questionnaire score of 2 or greater at screening&#xD;
&#xD;
          -  Failure of medical therapy to provide relief of symptoms&#xD;
&#xD;
          -  Spirometry 15 minutes after administration of bronchodilator (BOTH):&#xD;
&#xD;
               -  FEV1 &lt; 50 % predicted.&#xD;
&#xD;
               -  FEV1/FVC ratio &lt;70 %&#xD;
&#xD;
          -  Lung volumes by plethysmography (BOTH):&#xD;
&#xD;
               -  Total Lung Capacity (TLC) &gt; 100 % predicted&#xD;
&#xD;
               -  Residual Volume (RV) &gt; 150 % predicted&#xD;
&#xD;
          -  Diffusing Capacity of Carbon Monoxide(DLco) &gt; = 20 and &lt; = 60 percent predicted&#xD;
&#xD;
          -  Oxygen saturation (SpO2) &gt; 90 % on &lt; or = 4 L/min supplemental O2, at rest&#xD;
&#xD;
          -  Six-Minute Walk Test distance &gt; or = 150 m&#xD;
&#xD;
          -  Abstinence from smoking for at least 16 weeks prior to screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior lung volume reduction surgery, prior lobectomy or pneumonectomy, or prior lung&#xD;
             transplantation&#xD;
&#xD;
          -  Requirement for ventilator support (invasive or non-invasive)&#xD;
&#xD;
          -  Three (3) or more COPD exacerbations requiring hospitalization within 1 year of&#xD;
             Screening visit or a COPD exacerbation requiring hospitalization within 8 weeks of&#xD;
             Screening visit&#xD;
&#xD;
          -  Pulmonary hypertension, defined as:&#xD;
&#xD;
               -  Echocardiogram with estimated peak systolic pressure &gt; 45 mmHg in the presence of&#xD;
                  tricuspid valve regurgitation stated in the echocardiogram report&#xD;
&#xD;
               -  If the echocardiogram shows peak systolic pressure &gt; 45 mmHg, right heart&#xD;
                  catheterization is required to rule out pulmonary hypertension, defined as peak&#xD;
                  systolic pressure &gt; 45 mmHg or mean pressure &gt; 35 mmHg&#xD;
&#xD;
          -  Clinically significant asthma (reversible airway obstruction) or bronchiectasis&#xD;
&#xD;
          -  CT scan: Presence of the following radiologic abnormalities:&#xD;
&#xD;
               -  Pulmonary nodule on CT scan greater that 1.0 cm in diameter (Does not apply if&#xD;
                  present for 2 years or more without increase in size or if proven benign by&#xD;
                  biopsy/PET)&#xD;
&#xD;
               -  Radiologic picture consistent with active pulmonary infection, e.g., unexplained&#xD;
                  parenchymal infiltrate&#xD;
&#xD;
               -  Significant interstitial lung disease&#xD;
&#xD;
               -  Significant pleural disease&#xD;
&#xD;
               -  Giant bullous disease (a predominant bulla &gt; 10 cm in all dimensions &gt;1 / 3 of&#xD;
                  the hemithorax)&#xD;
&#xD;
          -  Use of systemic steroids &gt; 20 mg/day or equivalent, immunosuppressive agents,&#xD;
             heparins, oral anticoagulants (e.g., warfarin, dicumarol; note: antiplatelet drugs&#xD;
             including aspirin and clopidogrel are permitted)&#xD;
&#xD;
          -  Allergy or sensitivity to medications required to safely undergo AeriSeal System&#xD;
             treatment&#xD;
&#xD;
          -  Participation in an investigational study of a drug, biologic, or device not currently&#xD;
             approved for marketing within 30 days prior to the screening visit&#xD;
&#xD;
          -  Body mass index &lt; 15 kg/m2 or &gt; 35 kg/m2&#xD;
&#xD;
          -  Female patient pregnant or breast-feeding or planning to be pregnant in the next year&#xD;
&#xD;
          -  Significant comorbidity that carries prohibitive risks or is associated with less than&#xD;
             2-year expected survival, including any of the following:&#xD;
&#xD;
               -  HIV/AIDS&#xD;
&#xD;
               -  Active malignancy&#xD;
&#xD;
               -  Stroke or Transient Ischemia Attack (TIA) within 12 months of screening&#xD;
&#xD;
               -  Myocardial infarction within 12 months of screening&#xD;
&#xD;
               -  Congestive heart failure within 12 months of screening defined at clinical&#xD;
                  evidence of right or left hear failure or left ventricular ejection fraction &lt; 45&#xD;
                  % on echocardiogram&#xD;
&#xD;
          -  Any condition that the Investigator believes would interfere with the intent of the&#xD;
             study or would make participation not in the best interest of the patient such as&#xD;
             alcoholism, high risk for drug abuse or noncompliance in returning for follow-up&#xD;
             visits&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Felix Herth, Prof. Dr med</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thoraxklinik am Uniklinikum Heidelberg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wolfgang Gesierich, Dr med</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asklepios Fachkliniken Muenchen - Gauting</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manfred Wagner, Dr med</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum Nuernberg Nord</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mordechai Kramer, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rabin Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Hetzel, Dr med</last_name>
    <role>Principal Investigator</role>
    <affiliation>Krankenhaus vom Roten Kreuz - Stuttgart</affiliation>
  </overall_official>
  <verification_date>November 2013</verification_date>
  <study_first_submitted>July 18, 2013</study_first_submitted>
  <study_first_submitted_qc>July 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2013</study_first_posted>
  <last_update_submitted>November 13, 2013</last_update_submitted>
  <last_update_submitted_qc>November 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Emphysema</keyword>
  <keyword>Heterogeneous Lower Lobe Predominant Emphysema</keyword>
  <keyword>Heterogeneous Upper and Lower Lobe Predominant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Pulmonary Emphysema</mesh_term>
    <mesh_term>Emphysema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

